Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

References

• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• FerrerMMenendezRAmaroRTorresAThe impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumoniaClin Chest Med201132349150521867818
   PubMed Web of Science ®Google Scholar
• McCabeCKirchnerCZhangHDaleyJFismanDNGuideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rulesArch Intern Med2009169161525153119752411
   PubMedGoogle Scholar
• DoernGVRichterSSMillerAAntimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?Clin Infect Dis200541213914815983908
   PubMed Web of Science ®Google Scholar
• LynchJPIIIZhanelGGEscalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapySemin Respir Crit Care Med200526657561616388429
   PubMed Web of Science ®Google Scholar
• LynchJPIIIZhanelGGStreptococcus pneumoniae: does antimicrobial resistance matter?Semin Respir Crit Care Med200930221023819296420
   PubMed Web of Science ®Google Scholar
• PallaresRLiñaresJVadilloMResistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, SpainN Engl J Med199533384744807623879
   PubMed Web of Science ®Google Scholar
• TleyjehIMTlaygehHMHejalRMontoriVMBaddourLMThe impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysisClin Infect Dis200642678879716477555
   PubMed Web of Science ®Google Scholar
• FalcóVAlmiranteBJordanoQInfluence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?J Antimicrob Chemother200454248148815215226
   PubMed Web of Science ®Google Scholar
• AspaJRajasORodríguez de CastroFDrug-resistant pneumococcal pneumonia: clinical relevance and related factorsClin Infect Dis200438678779814999620
   PubMed Web of Science ®Google Scholar
• TurettGSBlumSFazalBAJustmanJETelzakEEPenicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalenceClin Infect Dis199929232132710476736
   PubMed Web of Science ®Google Scholar
• MetlayJPHofmannJCetronMSImpact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumoniaClin Infect Dis200030352052810722438
   PubMed Web of Science ®Google Scholar
• WhitbyMMcLawsMLBerryGRisk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysisMed J Aust2001175526426711587259
   PubMed Web of Science ®Google Scholar
• CosgroveSESakoulasGPerencevichENComparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysisClin Infect Dis2003361535912491202
   PubMed Web of Science ®Google Scholar
• TanejaCHaqueNOsterGClinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumoniaJ Hosp Med20105952853420734457
   PubMed Web of Science ®Google Scholar
• BoucherHWCoreyGREpidemiology of methicillin-resistant Staphylococcus aureusClin Infect Dis200846Suppl 5S344S34918462089
   PubMed Web of Science ®Google Scholar
• DavidMZDaumRSCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicClin Microbiol Rev201023361668720610826
   PubMed Web of Science ®Google Scholar
• PatelMCommunity-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and managementDrugs200969669371619405550
   PubMed Web of Science ®Google Scholar
• RosenthalVDMakiDGJamulitratSInternational Nosocomial Infection Control Consortium (INICC) report, data summary for 2003–2008 issued Jun 2009Am J Infect Control201038295104e220176284
   PubMed Web of Science ®Google Scholar
• TenoverFCGoeringRVMethicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiologyJ Antimicrob Chemother200964344144619608582
   PubMed Web of Science ®Google Scholar
• Labandeira-ReyMCouzonFBoissetSStaphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumoniaScience200731558151130113317234914
   PubMed Web of Science ®Google Scholar
• HotaBLylesRRimJPredictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumoniaClin Infect Dis201153875776521880583
   PubMed Web of Science ®Google Scholar
• StryjewskiMECoreyGRNew treatments for methicillin-resistant Staphylococcus aureusCurr Opin Crit Care200915540341219561492
   PubMed Web of Science ®Google Scholar
• Villegas-EstradaALeeMHesekDVakulenkoSBMobasherySCo-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibioticsJ Am Chem Soc2008130299212921318582062
   PubMed Web of Science ®Google Scholar
• Kosowska-ShickKMcGheePLAppelbaumPCAffinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniaeAntimicrob Agents Chemother20105451670167720194704
   PubMed Web of Science ®Google Scholar
• MoisanHPruneauMMalouinFBinding of ceftaroline to penicillin- binding proteins of Staphylococcus aureus and Streptococcus pneumoniaeJ Antimicrob Chemother201065471371620097788
   PubMed Web of Science ®Google Scholar
• SaderHSFritscheTRKanigaKGeYJonesRNAntimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strainsAntimicrob Agents Chemother20054983501351216048970
   PubMed Web of Science ®Google Scholar
• GeYBiekDTalbotGHSahmDFIn vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United StatesAntimicrob Agents Chemother20085293398340718625769
   PubMed Web of Science ®Google Scholar
• BrownSDTraczewskiMMIn vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testingAntimicrob Agents Chemother20095331271127419114671
   PubMed Web of Science ®Google Scholar
• SaravolatzLDPawlakJJohnsonLBIn vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)Int J Antimicrob Agents2010361697220413274
   PubMed Web of Science ®Google Scholar
• JacobsMRGoodCEWindauARActivity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United StatesAntimicrob Agents Chemother20105462716271920308374
   PubMed Web of Science ®Google Scholar
• JonesRNFarrellDJMendesRESaderHSComparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance studyJ Antimicrob Chemother201166Suppl 3iii69iii8021482572
   PubMed Web of Science ®Google Scholar
• KaushikDRathiSJainACeftaroline: a comprehensive updateInt J Antimicrob Agents201137538939521420284
   PubMed Web of Science ®Google Scholar
• JonesRNFritscheTRGeYKanigaKSaderHSEvaluation of PPI- 0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion testsJ Antimicrob Chemother20055661047105216239290
   PubMed Web of Science ®Google Scholar
• FenollAAguilarLRobledoOIn vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaximeAntimicrob Agents Chemother200852114209421018725443
   PubMed Web of Science ®Google Scholar
• McGeeLBiekDGeYIn vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniaeAntimicrob Agents Chemother200953255255619015339
   PubMed Web of Science ®Google Scholar
• Croisier-BertinDPirothLCharlesPECeftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosingAntimicrob Agents Chemother20115573557356321576444
   PubMed Web of Science ®Google Scholar
• RichterSSSatolaSWCrispelEKDetection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United StatesJ Clin Microbiol201149124203420721976769
   PubMed Web of Science ®Google Scholar
• SteedMVidaillacCRybakMJEvaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic modelAntimicrob Agents Chemother20115573522322621576449
   PubMed Web of Science ®Google Scholar
• SteedMERybakMJCeftaroline: a new cephalosporin with activity against resistant gram-positive pathogensPharmacotherapy201030437538920334458
   PubMed Web of Science ®Google Scholar
• ZhanelGGSniezekGSchweizerFCeftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureusDrugs200969780983119441869
   PubMed Web of Science ®Google Scholar
• LaudanoJBCeftaroline fosamil: a new broad-spectrum cephalosporinJ Antimicrob Chemother201166Suppl 3iii11iii1821482565
   PubMed Web of Science ®Google Scholar
• KanafaniZACoreyGRCeftaroline: a cephalosporin with expanded gram-positive activityFuture Microbiol200941253319207097
   PubMed Web of Science ®Google Scholar
• GeYMaynardDRickertDEComparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injectionAntimicrob Agents Chemother201054291292419949051
   PubMed Web of Science ®Google Scholar
• JacquelineCCaillonJBatardEEvaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis modelJ Antimicrob Chemother201065102264226520716553
   PubMed Web of Science ®Google Scholar
• AndesDCraigWAPharmacodynamics of a new cephalosporin, PPI- 0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic targetAntimicrob Agents Chemother20065041376138316569855
   PubMed Web of Science ®Google Scholar
• FileTMJrLowDEEckburgPBIntegrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumoniaClin Infect Dis201051121395140521067350
   PubMed Web of Science ®Google Scholar
• CritchleyIAEckburgPBJandourekABiekDFriedlandHDThyeDAReview of ceftaroline fosamil microbiology: integrated FOCUS studiesJ Antimicrob Chemother201166Suppl 3iii45iii5121482569
   PubMed Web of Science ®Google Scholar
• CorradoMLIntegrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv67iv7121115456
   PubMed Web of Science ®Google Scholar
• PanagiotidisGBäckströmTAsker-HagelbergCJandourekAWeintraubANordCEEffect of ceftaroline on normal human intestinal microfloraAntimicrob Agents Chemother20105451811181420231399
   PubMed Web of Science ®Google Scholar
• CoreyGRWilcoxMTalbotGHIntegrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infectionClin Infect Dis201051664165020695801
   PubMed Web of Science ®Google Scholar
• ClarkCKosowska-ShickKMcGheePMultistep resistance development studies of ceftaroline (CPT) with Haemophilus influenzae and Oraxella catarrhalisAbstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and ChemotherapyBoston, MA2010American Society for MicrobiologyWashington DC, USA Poster #E-814
   Google Scholar
• ClarkCKosowska-ShickKMcGheePMultistep resistance development studies of ceftaroline (CPT) with Streptococcus pneumoniae, Streptococcus pyogenes, staphylococci, and enterococciAbstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and ChemotherapyBoston, MA2010American Society for MicrobiologyWashington DC, USA Poster #E-813
   Google Scholar
• IshikawaTNakayamaYTomimotoMStudies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administrationJ Antibiot (Tokyo)200154436437411426661
   PubMed Web of Science ®Google Scholar
• Teflaro™. Package insertSt Louis, Missouri, USAForest Pharmaceuticals Inc.12011
   Google Scholar
• WiskirchenDECrandonJLFurtadoGHWilliamsGNicolauDPIn vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)- producing and non-ESBL-producing EnterobacteriaceaeAntimicrob Agents Chemother20115573220322521518838
   PubMed Web of Science ®Google Scholar